I-Skin Rash kunye nezinye izibonakaliso ngenxa yeTarceva (Erlotinib)
Ukuba uye wabhekana ne-acne-like rash, isikhumba esomileyo, ukubetha, kunye ne-nail utshintsha ngelixa uthatha iTarceva (erlotinib) awunabo. Kubantu abathile abanomdlavuza wamaphaphu, unyango olujoliswe kuTarceva (erlotinib,) kunye nezinye i-epidermal growth factor receptor (EGFR) inhibitors, baye bazibuza izidakamizwa ngendlela eya kubantu abane-EGFR emihle yomdlavuza wamaphaphu. Ezi zonyango ziye zaphucula umgangatho wobomi ngelixa ziphila nomhlaza, zisinda, kwaye zidla ngeempembelelo ezimbalwa kunezendalo zendalo.
Enye impembelelo yecala, nangona kunjalo, ifumene ingqwalasela eninzi: iingxaki zesikhumba
Uninzi lwabantu basebenzisa iyeza iTarceva (kunye nezinye i-EGFR inhibitors) zihlakulela ukukhawuleza, kwaye ngokuthakazelisayo, ukubonakala kwe-rash kuye kwahambelana nokuphendula kwisilwanyana. Ekubeni eli liyeza lithathwa ixesha elide, kubaluleke kakhulu ukuxoxa ngokuphathwa kwanoma yimaphi iimpawu ezingathandekiyo nge-oncologist yakho.
(Ukuba unomdlavuza wamaphaphu, ikakhulukazi umphunga adenocarcinoma, qinisekisa ukuba ugqirha wakho wenze uvavanyo lwemizimba (iprofile yamaphrofayili) yesisu sakho.)
Ziziphi iintlobo zeengxaki zesikhumba eziqhelekileyo kunye neTarceva (Erlotinib)?
Iingxaki zesikhumba eziqhelekileyo abantu abazenzayo kwiTarceva (kunye nezinye i-epidermal growth factor inhibitors) ziquka:
- Uhlobo lwe-acne rash (u-rash acneiform) - Olu qhekeza luvame ukufana ne-acne ebonwayo kwintsha. Ngokuqhelekileyo kubandakanya ubuso, ummandla emva kweendlebe, entanyeni, kwisiqongo esiphezulu kwipateni ene-V, kunye ne-scalp. Ngokuqhelekanga kuyachaphazela umva osezantsi, isisu, izibonda, kunye nemigangatho ephezulu nangaphantsi. Ukukhahlela akuveli kwiintendelezo zezandla okanye iinyawo. Isigama sesigxina sinokudideka xa ufunda ulwazi malunga nokukhawuleza, kodwa iingcaciso ezimbalwa ezilula zinokukunceda. I-papule ithetha nje ukuhlamba kwesikhumba. I-pustule ithetha i-bump ejongene nefuthe egciniweyo okanye idityayo. Ixesha elithi follicular lithetha nje ukuba izilonda zesikhumba ziphantse okanye kwi-follicle yeenwele.
- Ikhumba elomileyo (xeroderma)
- Ukutshiza (pruritis)
- Iintlanzi ezantsi kwinqanaba le-fingernail okanye inenail (paronychia)
Ziyayimfuneko kangakanani iRash?
Uninzi lwabantu baphathwe ngamachiza afana neTarceva anesibindi sokuqhathaniswa kwesikhumba, ngokuqhelekileyo uhlobo lokugqithisa olufana ne-acne, kunye nekhumba elomileyo.
Impact yeengxaki zesikhumba zaseTarceva
Ingxaki zesikhumba kwi-epidermal growth factor receptor inhibitors zinokuchaphazela kakhulu umgangatho wobomi kunye nomoya wobomi kubantu abathabatha la mayeza.
Olunye uphando lufumene ukuba ezi ziphumo zempembelelo zathintela impilo, izimo, zengqondo, kunye nentlalontle yabantu kwizigulana. Izikhalazo eziqhelekileyo ziphathelele iimpawu zomzimba, kuquka intlungu, ukuvutha komlilo kunye nobutyebi.
Ixesha Eliphi I-Rash Lwenzeka Kwenzeka Kangakanani?
Ukugqithisa isikhumba kwiTarceva kuvame ukuqala iiveki ezi-1 ukuya kwezi-2 emva kokuba unyango luqalisiwe, zikwimizuzu yazo e-2 ukuya kweyesithathu emva kokuba unyango luqalise, kwaye lunokugqiba okanye luphele ngokusisigxina kwiinyanga ezizayo ezi-2 ukuya kwezi-3. Ukwazi ukuba ukukhawuleza kuthatha ukuphucula ngokuhamba kwexesha kuye kwabanceda abanye abantu ukuba banyamezele iimpawu.
Ngaba iRash ithetha ukuba i-Tarceva iSebenza kangcono?
Uphando lubonisa ukuba abantu abahlakulela ukugqithiswa kwezilwanyana banezinga eliphezulu lokuphendula kunye nokuphila ngokubhetele. Ngenxa yoko, kwaye ngenxa yokuba isilwanyana sisoloko sithathwa kwixesha elide, kubaluleke kakhulu ukuba kusebenze ukunyanga iimpawu zokukhawuleza.
Iingxaki zesikhumba ezihlobene nezinye izifo zonyango ezifana ne-chemotherapy kunye neyeza zonyango zingaba kunye nezo zivela eTarceva kwaye kufuneka ziqwalaselwe ngokucophelela nge-oncologist yakho.
Ubunzima beRash
Uhlobo lwe-Acne uhla lwe-Acne ngenxa yeTarceva luvame ukuphuka ukuya kwiintlobo ezi-3:
- Ubumnandi: I-Tarceva ecacileyo ichazwa njengomntu ongenasilonda (iindawo ezivulekileyo) ukulila (umsele) okanye usulelo. Abantu bahlala bephethe iimpawu ezinobuliso kwaye abaphazamisi imisebenzi eqhelekileyo yobomi.
- I-Moderate: Ukukhawuleza kweTarceva kungabakho ndawo okanye kudala. Ngokuqhelekileyo akukho sisilonda, ukulila okanye ukusuleleka. Iimpawu ezincinci zokumodareyitha kunye nokuthabatha inokuba khona, kodwa kunokuphazamiseka okuncinci kwimisebenzi yobomi.
- Ukuqatha: I-Tarceva eqhelekileyo ixakeka ngokuqhelekileyo (igubungela ubuso, isifuba esiphezulu, kunye nomqolo ongentla) kwaye idla ngokuhambisana nempawu ezinzima zokubamba nokunyamezela. Ichaphazela kakhulu umgangatho wobomi. Kukhona isilonda (izilonda ezivulekileyo) ukulila (umsele) kunye nempawu zentsholongwane yesibini efana nolubomvu, ukutshatyalaliswa okwesibhakabhaka okanye ukukhupha okomhlaza kunye nomkhuhlane.
Ukuhlambalaza kwezikhumba kuTarceva kuthathwa njani?
Indlela okuza kunyangwa ngayo iya kuxhomekeka kububungqina bokukhawuleza, kunye nezikhetho zakho. Nangona i-rash ifana ne-acne, akusiyo i-acne ersh, kwaye ayiyi kuphendula kwiindlela ezininzi zonyango.
I-Tarceva (Erlotinib) I-Rash Prevention kunye noNonophelo lweNsuku zonke
Isinyathelo sokuqala ekulawulweni kukuthintela: Izicwangciso zokukhusela ziquka ukugcina ulusu lucocekile, ukuphepha ukutshiswa kwelanga, nokusebenzisa i-moisturizers ukugcina ulusu lwakho luhlanjululwe. Ubhedu olungcono kakhulu ekukhuseleni ukushona kwelanga kukugwema ukukhanya kwelanga phakathi kwemini, kwaye usebenzise iimpahla zokukhusela, njengokuba i-sunscreens kunye ne-sunblocks ingenza i-Tarceva-induced irouss worse. Ukusebenza ngokukhawuleza ngeemveliso ze-vasel kungenza ukwandisa ukunyuka kweenwele kunye nokugqithisa. (Khangela ezi ngcebiso malunga nokuphepha kwelanga ngexesha lotyando lomhlaza .)
Kubalulekile ukuba uqaphele ukuba unyango lwesinye uphawu oluhambelana neTarceva lunokugqithisa esinye isibonakaliso kunye nesimo salo. Ngokomzekelo, i-moisturizers inokukunceda ngokumisa nokubetha kodwa kuphazamise ukuhlaselwa kwe-acne type.
I-Tarceva (Erlotinib) iRash Treatments
Ukunyangwa kwe-Tarceva ukugqithisa kuxho mekeke ukuba ingaba i-rash isetyholongwane okanye ayiyi kubandakanywa kokubili ukuphatha i-rash, okanye ukuguqula idosi. Ezi zikhethi zingabandakanya:
Iintlobo zonyango:
- Iingcebiso zonyango: Iingqungquthela ze-antibiotic ezifana ne-clindamycin kunye / okanye i-hydrocortisone ye-topical ihlala isetyenziselwa okokuqala ukuze i-acne-type Tarceva ihlaziye. Izifundo zijonge ukusetyenziswa kwe-vitamin K cream, kunye ne-epidermal yokukhula kwamafutha, apho bobabini babonise isithembiso kwizilingo zeklinikhi. Kubalulekile ukuphinda uqaphele ukuba nangona ukugqithisa kufana ne-acne, akunjalo, kwaye unyango oluninzi lwe-acne aluyi kukunceda ngokukhawuleza.
- Ionyango zomlomo: Ukuba unyango lwamayeza aluvumelekanga, unyango lomlomo ngee-antibiotic ezahlukeneyo ze-tetracycline lungasetyenziswa. Izifundo zijonge nokusetyenziswa kwezonyango zomlomo, ezifana nomlomo we-minocycline njengonyango lweprophylactic; iqalile ngaphambi kokuba kuqhutywe ukukhawuleza.
Ukunyangwa kwe-Rash Alone: Ukuba iimpawu ziquka ukukhwabanisa obomvu kuphela ngaphandle kweempawu zentsholongwane, uphathwa nge-steroids ye-topical, i-1% i-hydrocortisone, okanye i-2.5% xa ukugqithisa kunzima. Kule meko, kukho ubomvu kodwa akukho mhlophe emhlophe eya kubonisa ukuba usulelo lukhoyo.
Ukunyangwa kweRash R Infected: Xa ukugqithiswa kweTarceva kunzima ngosulelo lwebhakteria lwesibini abukho ubomvu kuphela kodwa ngokuqhelekileyo luphawu lweentsholongwane ezinjengeemhlophe. Xa kunjalo, unyango kufuneka lubandakanye zombini i-antibiotics yomlomo (i-tetracyclines) kunye ne-gel clindamycin.
Ukulungiswa kwesisombululo : Amaphesenti angama-10 abantu ahlakulela ukugqithisa okufuna ukuguqulwa kwamachiza. Umlinganiselo "oqhelekileyo" weTarceva ngu-150 mg imihla ngemihla. I-oncologist yakho ingaqwalasela ukunciphisa le dosi ukuya kwi-100 mg okanye nokuba ngu-50 mg ngosuku. Oku kuya kunkwantya, ingakumbi ukuba unyango lusebenza kakuhle kuwe. Kunokukunceda ukuba uqaphele ukuba kwanamanani aphantsi kakhulu eTarceva, aphantsi kwama-25 mg imihla ngemihla, sele ephumelele ekuphatheni abanye abantu abanomdlavuza wamaphaphu.
> Imithombo:
> I-American Society of Clinic Oncology. I-Cancer.net Iingxaki zesikhumba kwizonyango ezijoliswe kuzo. Ufikelele kwi-05/2016. http://www.cancer.net/kuvakalisa-coco-coco-catshu-
> Burotto, M., Manasanch, E., Wilkerson, J., noT. Fojo. I-Gefitinib kunye ne-erlotinib kwi-metastatic non-small small cell cell cancer: i-meta-analysis of thexicity and effectiveness of tests. Oncologist . 2015. 20 (4): 400-10.
> Califano, R. et al. Ingqungquthela yoLwazi malunga nokuPhathwa kweziganeko ezimbi ezivela kwi-EGFR iTrorosine Kinase Inhibitors e-UK. Zi yobisi . 2015. 75 (12): 1335-48.
> Fabbrocini, G., Panariello, L., Caro, G., no S. Cacciapuoti. I-Acneiform Rash Ekhutshwe yi-EGFR Inhibitors: Ukuhlaziywa kweeNcwadi kunye neNgcaciso emitsha .. Iziphazamiso ze-Skin Appendage . 2015. 1: 31-37.
> Hwang, I. et al. Isivivinyo sesiGaba sesi-II se-epidermal ukukhula kwamafutha okugulisa izigulane ezineempembelelo ezinxulumene nezikhumba ze-Erlotinib. Unonophelo loNcedo kwiCancer . 2015 Juni 4. (Epub ngaphambi kokuprinta).
> Kiyohara, Y., Yamazaki, N., no A. Kishi. Ulwaphulo olunxulumene nolwaphulo lwe-Erlotinib: izicwangciso zonyango kwizigulane ezinomdla wesifo se-metastatic non-small cell. Umbhalo we-American Academy of Dermatology . 2013. 69 (3): 463-72.
> Ocvirk, J., Heeger, S., McCloud, P., no R. Hofheinz. Ukuphononongwa kweendlela zokonyango kwesikhumba esenziwa ngu-EGFR-uphethwe ngonyango: Ubungqina obuvela kwiimvavanyo zeklinikhi ezingenamsebenzi kunye nohlalutyo lweemeta. I-Radiology ne-Oncology . 2013. 47 (2): 166-75.
> Passaro, A. et al. ukulawulwa kwee-nonhematologic toxicities ezinxulumene nee-EGFR-TKI ezahlukahlukeneyo kwi-NSCLC ephakamileyo: uhlalutyo lothelekiso. Cancer Lung Cancer . 2014. 15 (4): 307-12.
> Shinohara, A. et al. Ukusebenza kweprophylactic unyango lwe-minocycline yecyxicity eyenziwa yi-erlotinib kunye ne-gemcitabine kwizigulane ezinomdlavuza ophuthumayo we-pancreatic: i-study back. I-American Journal ye-Clinical Dermatology . 2015. 16 (3): 221-9.
> Szejiniuk, W., McCullock, T., kunye no-O. Roe. Ukuphumelela kwe-ultra-low dose erlotinib kwizigulane ezine-EGFR ezenza ukuguqulwa komzimba. Imibiko yee-BMJ Case . 2014. I-Doi: 10.1136 / bcr-2014-204809.